{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:53:57Z","timestamp":1760266437398},"reference-count":32,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2004,5,1]],"date-time":"2004-05-01T00:00:00Z","timestamp":1083369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2004,5]]},"DOI":"10.1016\/j.ijpharm.2004.01.030","type":"journal-article","created":{"date-parts":[[2004,3,17]],"date-time":"2004-03-17T10:36:34Z","timestamp":1079519794000},"page":"61-72","source":"Crossref","is-referenced-by-count":21,"title":["Leucinostatin-A loaded nanospheres: characterization and in vivo toxicity and efficacy evaluation"],"prefix":"10.1016","volume":"275","author":[{"given":"Maurizio","family":"Ricci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Giovagnoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luana","family":"Perioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Vescovi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2004.01.030_BIB1","doi-asserted-by":"crossref","first-page":"S841","DOI":"10.1093\/clinids\/17.Supplement_2.S481","article-title":"Infections with Aspergillus species","volume":"17","author":"Andriole","year":"1993","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0924-8579(00)00258-2","article-title":"Current and future antifungal therapy: new targets for antifungal therapy","volume":"16","author":"Andriole","year":"2000","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF01967060","article-title":"Fungal infection in cancer patients: an international autopsy survey","volume":"11","author":"Bodey","year":"1992","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1023\/A:1006905331276","article-title":"Human defenses against Cryptococcus neoformans: an update","volume":"143","author":"Brummer","year":"1999","journal-title":"Mycopathologia"},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB5","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S1473-3099(02)00371-7","article-title":"Antifungal drug resistance to azoles and polyenes","volume":"2","author":"Canuto","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB6","first-page":"209","article-title":"Two phytotoxic antibiotic peptides produced by submerged cultures of Paecilomyces marquandii (Massee) Hughes","volume":"22","author":"Casinovi","year":"1983","journal-title":"Phytopathol. Medit."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB7","first-page":"527","article-title":"The structure of Leucinostatin C. A minor peptide from Paecylomyces marquandii","volume":"21","author":"Casinovi","year":"1986","journal-title":"Eur. J. Med. Chem. Chim. Ther."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0167-4889(94)90004-3","article-title":"The nonapeptide leucinostatin A acts as a weak ionophore and as an immunosuppressant on T lymphocytes","volume":"1221","author":"Csermely","year":"1994","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.43.1.1","article-title":"Antifungal peptides: novel therapeutic compounds against emerging pathogens","volume":"43","author":"De Lucca","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB10","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0161-5890(02)00022-6","article-title":"Invasive fungal infections: evolving challenges for diagnosis and therapeutics","volume":"38","author":"Ellis","year":"2002","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0168-3659(00)00364-3","article-title":"Effects of emulsifiers on the controlled release of paclitaxel (Taxol\u00ae) from nanospheres of biodegradable polymers","volume":"71","author":"Feng","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1006\/jcis.2000.6816","article-title":"Antimicrobial nonapeptide Leucinostatin A dependent effects on physical properties of phospholipid model membranes","volume":"226","author":"Fresta","year":"2000","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB13","first-page":"104","article-title":"Future of antimycotic therapy","volume":"3","author":"Ghannoum","year":"1997","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB14","first-page":"275","article-title":"Leucinostatins, peptide mycotoxins produced by Paecilomyces lilacinus and their possible roles in fungal infection","volume":"257","author":"Mikami","year":"1984","journal-title":"Zbl. Bakt. Hyg."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB15","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0732-8893(98)00107-2","article-title":"Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure","volume":"32","author":"Milan","year":"1998","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0002-9343(95)00010-0","article-title":"The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance","volume":"100","author":"Nguyen","year":"1996","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0168-3659(93)90097-O","article-title":"Preparation of biodegradable nanospheres of water soluble and insoluble drugs with d,l-lactide\/glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior","volume":"25","author":"Niwa","year":"1993","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/jps.2600830527","article-title":"l-Lactide\/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method","volume":"83","author":"Niwa","year":"1994","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB19","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/S0968-0896(99)00176-5","article-title":"The comparison of characteristics between membrane-active antifungal peptide and its pseudopeptides","volume":"7","author":"Oh","year":"1999","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB20","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1046\/j.1469-0691.2002.00488.x","article-title":"Pneumonia due to Candida krusei","volume":"8","author":"Petrocheilou-Paschou","year":"2002","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB21","doi-asserted-by":"crossref","unstructured":"Ricci, M., Sassi, P., Nastruzzi, C., Rossi, C., 2000. Liposome-based formulations for the antibiotic nonapeptide Leucinostatin A. FTIR spectroscopic characterization and in vivo toxicological study. AAPS Pharm. Sci. Tech. 1 (article 2).","DOI":"10.1007\/BF02830517"},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.7164\/antibiotics.40.130","article-title":"Leucinostatin D, a novel peptide antibiotic from Paecilomyces marquandii","volume":"40","author":"Rossi","year":"1987","journal-title":"J. Antibiot."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB23","first-page":"109","article-title":"Leucinostatin F. A minor co-metabolite","volume":"1","author":"Rossi","year":"1990","journal-title":"Acta Technol. Legis Med."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/CMR.12.1.40","article-title":"Current and emerging azole antifungal agents","volume":"12","author":"Sheehan","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1247\/csf.15.53","article-title":"Dual inhibitory effects of the peptide antibiotics leucinostatins on oxidative phosphorylation in mitochondria","volume":"15","author":"Shima","year":"1990","journal-title":"Cell Struct. Funct."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0005-2736(99)00086-3","article-title":"Membrane channel formation by antimicrobial protegrins","volume":"1420","author":"Sokolov","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB27","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0168-9452(97)00131-3","article-title":"Acremonium sp.\u2014a leucinostatin A producing endophyte of European yew (Taxus baccata)","volume":"128","author":"Strobel","year":"1997","journal-title":"Plant Sci."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1574-6968.1998.tb12896.x","article-title":"Mechanism of antimicrobial action of indolicidin","volume":"160","author":"Subbalakshmi","year":"1998","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0732-8893(99)00035-8","article-title":"Nosocomial fungal infections: candidemia","volume":"34","author":"Verduyn Lunel","year":"1999","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1034\/j.1399-3062.1999.010404.x","article-title":"Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century","volume":"1","author":"Walsh","year":"1999","journal-title":"Transplant Infect. Dis."},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1054\/drup.1999.0092","article-title":"Antifungal drug susceptibility testing and resistance in Aspergillus","volume":"2","author":"Warnock","year":"1999","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ijpharm.2004.01.030_BIB32","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/clinids\/20.1.115","article-title":"Importance of Candida species other than C. albicans as pathogens in oncology patient","volume":"20","author":"Wingard","year":"1995","journal-title":"Clin. Infect. Dis."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517304000596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517304000596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,31]],"date-time":"2020-03-31T17:09:28Z","timestamp":1585674568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517304000596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5]]},"references-count":32,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2004,5]]}},"alternative-id":["S0378517304000596"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2004.01.030","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2004,5]]}}}